Slajd 2

1. Papaioannou, Andriana I et al. “Towards precision medicine in severe asthma: Treatment algorithms based on treatable traits.” Respiratory medicine vol. 142 (2018): 15-22. doi:10.1016/j.rmed.2018.07.006

Slajd 3

1. Globalna Inicjatywa na rzecz Zwalczania Astmy (GINA). Globalna Strategia Leczenia i Profilaktyki Astmy (aktualizacja z 2023 r.). Dostępne pod adresem: https://ginasthma.org/wp-content/uploads/2023/07/GINA-2023-Full-report-23_07_06-WMS.pdf [dostęp: listopad 2023 r.].

Slajd 4

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Updated May 2023, Accessed May 2, 2023: https://ginasthma.org/gina-reports/

Slajd 5

1. Pavord ID, et al. J Allergy Clin Immunol Pract. 2022;10(2):410-419.

Slajd 6

1. Brusselle, Guy G, and Gerard H Koppelman. “Biologic Therapies for Severe Asthma.” The New England journal of medicine vol. 386,2 (2022): 157-171. doi:10.1056/NEJMra2032506

Slajd 7

1. Denton et al. J Allergy Clin Immunol Pract. 2021;9(7):2680-2688.e7

Slajd 8

1. Tran TN et al. Ann Allergy Asthma Immunol. 2016;116:37–42;
2. Denton E et al. J Allergy Clin Immunol Pract. 2021;9:2680–2688;
3. Kupczyk M et al. Allergy. 2014;69:1198–1204;

Slajd 9-18

1. Opis przypadku Dr n. med. Dorota Kierszniewska, Dr n. med. Izabela Kupryś-Lipińska, Dr n. med. Marta Kołacińska - Flont

Slajd 19

1. Jackson, David J et al. “Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study.” Lancet (London, England) vol. 403,10423 (2024): 271-281. doi:10.1016/S0140-6736(23)02284-5